EarlySense has brought a third strategic investor into its latest financing round, and Mitsui & Co. has partnered exclusively with the startup to market its continuous, contact-free patient monitoring solution to Japanese homes and hospitals.
IBM increased its presence in the device world in a major way, announcing a collaboration around famous supercomputer Watson with Medtronic, Johnson & Johnson and Apple.
Boston Scientific has partnered with Frankenman Medical Equipment to develop and manufacture products in China for that market. The pair also plans to jointly commercialize some products in China. The deal plays up Boston Scientific's strengths within its endoscopy group, which has struggled to keep pace with sales growth in the larger company.
AstraZeneca has signed on to partner with PatientsLikeMe to cull data from its network of some 250,000 patients that will help guide drug development at the pharma giant.
J&J's Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B.
Israel's Intec Pharma is discussing a partnership involving its drug-delivering Accordion Pill with a Big Pharma player. The deal contains an option that would net Intec up $150 million, in addition to royalties on product sales.
Multinational venture capital firm TVM Capital Life Science said its first close for China BioPharma Capital I reached $50 million aimed at "investments in life science innovation in Western companies with the objective to obtain licenses for development and commercialization in China," according to a news release.
Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B. The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.
Qualcomm has announced a deal with IT specialist Cerner to extend the capture of vital patient data from devices in the home and send it to healthcare providers monitoring their conditions.
Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's stem cell pipeline and a preferred spot at the bargaining table if it follows up with a licensing deal.